Detailed information for compound 400388

Basic information

Technical information
  • TDR Targets ID: 400388
  • Name: (3S)-3-[[(2S)-2-[[(2S)-2-acetamido-3,3-diphen ylpropanoyl]amino]-5-(diaminomethylideneamino )pentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[ [(2S)-1-hydroxy-3-(1H-indol-3-yl)-1-oxopropan -2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino] -3-methyl-1-oxopentan-2-yl]amino]-4-oxobutano ic acid
  • MW: 967.12 | Formula: C50H66N10O10
  • H donors: 11 H acceptors: 10 LogP: 3.98 Rotable bonds: 34
    Rule of 5 violations (Lipinski): 3
  • SMILES: CC[C@@H]([C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)Cc1c[nH]c2c1cccc2)[C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C(c1ccccc1)c1ccccc1)NC(=O)C)CCCNC(=N)N)CC(=O)O)C
  • InChi: 1S/C50H66N10O10/c1-6-28(3)41(46(66)58-38(49(69)70)25-33-27-54-35-22-15-14-21-34(33)35)60-47(67)42(29(4)7-2)59-45(65)37(26-39(62)63)57-44(64)36(23-16-24-53-50(51)52)56-48(68)43(55-30(5)61)40(31-17-10-8-11-18-31)32-19-12-9-13-20-32/h8-15,17-22,27-29,36-38,40-43,54H,6-7,16,23-26H2,1-5H3,(H,55,61)(H,56,68)(H,57,64)(H,58,66)(H,59,65)(H,60,67)(H,62,63)(H,69,70)(H4,51,52,53)/t28-,29-,36-,37-,38-,41-,42-,43-/m0/s1
  • InChiKey: YOMSYVFQYBPECD-TYTHOBKFSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • (3S)-3-[[(2S)-2-[[(2S)-2-acetamido-3,3-diphenyl-propanoyl]amino]-5-guanidino-pentanoyl]amino]-4-[[(1S,2S)-1-[[(1S,2S)-1-[[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)-2-oxo-ethyl]carbamoyl]-2-methyl-butyl]carbamoyl]-2-methyl-butyl]amino]-4-oxo-butanoic acid
  • (3S)-3-[[(2S)-2-[[(2S)-2-acetamido-1-oxo-3,3-diphenylpropyl]amino]-5-guanidino-1-oxopentyl]amino]-4-[[(1S,2S)-1-[[[(1S,2S)-1-[[[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]-oxomethyl]-2-methylbutyl]amino]-oxomethyl]-2-methylbutyl]amino]-4-oxobutanoic acid
  • (3S)-3-[[(2S)-2-[[(2S)-2-acetamido-3,3-diphenyl-propanoyl]amino]-5-[bis(azanyl)methylideneamino]pentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(2S)-1-hydroxy-3-(1H-indol-3-yl)-1-oxo-propan-2-yl]amino]-3-methyl-1-oxo-pentan-2-yl]amino]-3-methyl-1-oxo-pentan-2-yl]amino]-4-oxo-butanoic acid
  • (3S)-3-[[(2S)-2-[[(2S)-2-acetamido-3,3-diphenyl-propanoyl]amino]-5-guanidino-pentanoyl]amino]-4-[[(1S,2S)-1-[[(1S,2S)-1-[[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)-2-keto-ethyl]carbamoyl]-2-methyl-butyl]carbamoyl]-2-methyl-butyl]amino]-4-keto-butyric acid
  • (3S)-3-[[(2S)-2-[[(2S)-2-acetamido-3,3-di(phenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(2S)-1-hydroxy-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
  • (3S)-3-[[(2S)-2-[[(2S)-2-acetamido-3,3-di(phenyl)propanoyl]amino]-5-guanidino-pentanoyl]amino]-4-[[(1S,2S)-1-[[(1S,2S)-1-[[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)-2-oxo-ethyl]carbamoyl]-2-methyl-butyl]carbamoyl]-2-methyl-butyl]amino]-4-oxo-butanoic acid
  • (3S)-3-[[(2S)-2-[[(2S)-2-acetamido-1-oxo-3,3-di(phenyl)propyl]amino]-5-guanidino-1-oxopentyl]amino]-4-[[(1S,2S)-1-[[[(1S,2S)-1-[[[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)-2-oxoethyl]amino]-oxomethyl]-2-methylbutyl]amino]-oxomethyl]-2-methylbutyl]amino]-4-oxobutanoic acid
  • (3S)-3-[[(2S)-2-[[(2S)-2-acetamido-3,3-di(phenyl)propanoyl]amino]-5-guanidino-pentanoyl]amino]-4-[[(1S,2S)-1-[[(1S,2S)-1-[[(1S)-2-hydroxy-1-(1H-indol-3-ylmethyl)-2-keto-ethyl]carbamoyl]-2-methyl-butyl]carbamoyl]-2-methyl-butyl]amino]-4-keto-butyric acid
  • (3S)-3-[[(2S)-2-[[(2S)-2-acetamido-3,3-di(phenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-[[(2S,3S)-1-[[(2S,3S)-1-[[(2S)-1-hydroxy-3-(1H-indol-3-yl)-1-oxo-propan-2-yl]amino]-3-methyl-1-oxo-pentan-2-yl]amino]-3-methyl-1-oxo-pentan-2-yl]amino]-4-oxo-butanoic acid

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Rattus norvegicus Endothelin receptor ET-B Starlite/ChEMBL References
Homo sapiens endothelin receptor type B Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Onchocerca volvulus Endothelin receptor ET-B   442 aa 445 aa 20.9 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Leishmania major DNA topoisomerase IB, large subunit 0.0137 0.4135 1
Onchocerca volvulus 0.0026 0.0271 0.5
Echinococcus multilocularis DNA topoisomerase 1 0.0183 0.5742 0.5
Trypanosoma brucei DNA topoisomerase IB, large subunit 0.0137 0.4135 1
Brugia malayi DNA topoisomerase I 0.0183 0.5742 0.5623
Schistosoma mansoni glutaminase 0.0305 1 1
Echinococcus granulosus DNA topoisomerase 1 0.0183 0.5742 0.5
Loa Loa (eye worm) DNA topoisomerase I 0.0183 0.5742 0.5726
Loa Loa (eye worm) glutaminase 0.0305 1 1
Mycobacterium tuberculosis Probable fatty-acid-CoA ligase FadD2 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) 0.0026 0.0271 1
Loa Loa (eye worm) hypothetical protein 0.0026 0.0271 0.0234
Loa Loa (eye worm) glutaminase 2 0.0305 1 1
Mycobacterium leprae PROBABLE FATTY-ACID-CoA LIGASE FADD7 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) 0.0026 0.0271 0.5
Mycobacterium ulcerans long-chain fatty-acid CoA ligase 0.0026 0.0271 0.0234
Mycobacterium ulcerans hypothetical protein 0.0026 0.0271 0.0234
Mycobacterium tuberculosis Fatty-acid-AMP ligase FadD30 (fatty-acid-AMP synthetase) (fatty-acid-AMP synthase) 0.002 0.0038 0.139
Trichomonas vaginalis glutaminase, putative 0.0305 1 0.5
Entamoeba histolytica acyl-CoA synthetase, putative 0.0026 0.0271 0.5
Mycobacterium ulcerans acyl-CoA synthetase 0.0026 0.0271 0.0234
Plasmodium vivax topoisomerase I, putative 0.0183 0.5742 1
Chlamydia trachomatis acylglycerophosphoethanolamine acyltransferase 0.002 0.0038 0.5
Mycobacterium ulcerans fatty-acid-CoA ligase 0.0026 0.0271 0.0234
Mycobacterium ulcerans glutaminase 0.0305 1 1
Loa Loa (eye worm) hypothetical protein 0.0026 0.0271 0.0234
Mycobacterium ulcerans acyl-CoA synthetase 0.0026 0.0271 0.0234
Mycobacterium ulcerans long-chain-fatty-acid--CoA ligase 0.0026 0.0271 0.0234
Schistosoma mansoni DNA topoisomerase type I 0.0183 0.5742 0.274
Mycobacterium leprae PROBABLE FATTY-ACID-CoA LIGASE FADD2 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) 0.0026 0.0271 0.5
Mycobacterium ulcerans acyl-CoA synthetase 0.0026 0.0271 0.0234
Loa Loa (eye worm) hypothetical protein 0.0026 0.0271 0.0234
Entamoeba histolytica acyl-coA synthetase, putative 0.0026 0.0271 0.5
Toxoplasma gondii DNA topoisomerase I, putative 0.0183 0.5742 0.5
Mycobacterium tuberculosis Probable chain -fatty-acid-CoA ligase FadD13 (fatty-acyl-CoA synthetase) 0.0026 0.0271 1
Trypanosoma cruzi DNA topoisomerase IB, large subunit, putative 0.0137 0.4135 1
Entamoeba histolytica acyl-CoA synthetase, putative 0.0026 0.0271 0.5
Leishmania major DNA topoisomerase type IB small subunit 0.0046 0.0954 0.1767
Plasmodium falciparum topoisomerase I 0.0183 0.5742 1
Mycobacterium ulcerans long-chain-fatty-acid-CoA ligase 0.0026 0.0271 0.0234

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 0.004 uM Binding affinity against endothelin A receptor from rabbit renal vascular smooth muscles ChEMBL. 7636842
IC50 (binding) = 0.004 uM Binding affinity against endothelin A receptor from rabbit renal vascular smooth muscles ChEMBL. 7636842
IC50 (binding) = 0.01 uM Binding affinity against endothelin B receptor rat cerebellar membranes. ChEMBL. 7636842
IC50 (binding) = 0.01 uM Binding affinity against endothelin B receptor rat cerebellar membranes. ChEMBL. 7636842
IC50 (functional) = 0.014 uM Inhibition of ET-1 stimulated arachidonic acid release in rabbit renal vascular smooth muscle cells ChEMBL. 7636842
IC50 (functional) = 0.014 uM Inhibition of ET-1 stimulated arachidonic acid release in rabbit renal vascular smooth muscle cells ChEMBL. 7636842
IC50 (binding) = 0.59 uM Binding affinity measured in CHO cells stably transfected with the human endothelin B receptor ChEMBL. 7636842
IC50 (binding) = 0.59 uM Binding affinity measured in CHO cells stably transfected with the human endothelin B receptor ChEMBL. 7636842
Ratio (binding) = 59 Relative affinities for rat endothelin B receptor and human endothelin B receptor ChEMBL. 7636842

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.